Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
10th Mar 20102:26 pmRNSRule 8.3- (Consort Medical)
10th Mar 20102:16 pmRNSRule 8.3- Consort Medical PLC
8th Mar 201010:23 amRNSRule 8.3- (Consort Medical Plc)
4th Mar 201012:07 pmRNSDIRECTORSHIP
3rd Mar 201010:54 amRNSRule 8.3- Consort Medical Plc
2nd Mar 20101:07 pmRNSRule 8.3- Consort Medical Plc
2nd Mar 201012:55 pmRNSRule 8.3-Consort Medical Plc - Amendment
2nd Mar 201010:27 amRNSRule 8.3- Consort Medical plc
2nd Mar 20109:27 amRNSStatement re Possible Offer
1st Mar 201012:09 pmRNSRule 8.3- Consort Medical Plc
1st Mar 20107:00 amRNSRule 2.10 Announcement
26th Feb 20102:51 pmRNSPossible Offer
26th Feb 201011:16 amRNSStatement re Possible Offer
18th Feb 20101:21 pmRNSNotification of Major Interest in Shares
19th Jan 20102:13 pmRNSNotification of Transactions of Directors
15th Dec 20091:42 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Dec 20093:57 pmRNSDetails of Share Dealings
10th Dec 20097:00 amRNSINTERIM RESULTS
2nd Dec 200912:33 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
19th Nov 20096:22 pmRNSOffer Update
5th Nov 200912:38 pmRNSOffer Update
5th Nov 20098:59 amRNSRule 8.1- The Medical House Plc
4th Nov 20098:48 amRNSRule 8.1- The Medical House Plc
3rd Nov 200910:00 amRNSRule 8.1- The Medical House Plc
29th Oct 20094:23 pmRNSOffer Update
28th Oct 20092:07 pmRNSDetails of Share Dealings
15th Oct 20094:36 pmRNSOffer Update
13th Oct 200912:51 pmRNSDirectorate Change
5th Oct 20094:54 pmRNSDirector/PDMR Shareholding
28th Sep 200910:30 amRNSRule 8.1- The Medical House Plc
24th Sep 20097:00 amRNSOffer for The Medical House PLC
21st Sep 200912:32 pmRNSBlock Listing 6 Monthly Return
18th Sep 20097:00 amRNSInterim Management Statement
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
16th Sep 20094:20 pmRNSAnnual General Meeting
21st Aug 200912:16 pmRNSDetails of Share Dealings
14th Aug 200911:04 amRNSNotification of Major Interests in Shares
27th Jul 200911:46 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
21st Jul 20093:56 pmRNSBlock Listing Six Monthly Return
3rd Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amRNSPreliminary Results
18th Jun 20094:49 pmRNSBLOCK LISTING SIX MONTHLY RETURN
3rd Jun 20094:40 pmRNSSecond Price Monitoring Extn
3rd Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 20099:30 amRNSNotice of Results
2nd Jun 20095:12 pmRNSBlock Listing Six Monthly Return
27th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20092:19 pmRNSHolding(s) in Company
6th May 20091:14 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.